By Application
Hot products 
-
Mouse Anti-CFL1 Recombinant Antibody (CBFYC-1771) (CBMAB-C1833-FY)
-
Rat Anti-EMCN Recombinant Antibody (28) (CBMAB-E0280-FY)
-
Rabbit Anti-ABL1 (Phosphorylated Y185) Recombinant Antibody (V2-443434) (PTM-CBMAB-0001YC)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Rabbit Anti-AP2M1 (Phosphorylated T156) Recombinant Antibody (D4F3) (PTM-CBMAB-0610LY)
-
Mouse Anti-ATP1B3 Recombinant Antibody (1E9) (CBMAB-A4021-YC)
-
Mouse Anti-BIRC3 Recombinant Antibody (315304) (CBMAB-1214-CN)
-
Mouse Anti-4-Hydroxynonenal Recombinant Antibody (V2-502280) (CBMAB-C1055-CN)
-
Mouse Anti-FOSB Recombinant Antibody (CBXF-3593) (CBMAB-F2522-CQ)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Mouse Anti-dsRNA Recombinant Antibody (2) (CBMAB-D1807-YC)
-
Mouse Anti-ALDOA Recombinant Antibody (A2) (CBMAB-A2316-YC)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-ALPL Antibody (B4-78) (CBMAB-1009CQ)
-
Rabbit Anti-CCL5 Recombinant Antibody (R0437) (CBMAB-R0437-CN)
-
Mouse Anti-AKR1C3 Recombinant Antibody (V2-12560) (CBMAB-1050-CN)
-
Mouse Anti-DDC Recombinant Antibody (8E8) (CBMAB-0992-YC)
-
Mouse Anti-AHCYL1 Recombinant Antibody (V2-180270) (CBMAB-A1703-YC)
-
Mouse Anti-AQP2 Recombinant Antibody (G-3) (CBMAB-A3359-YC)
Prostate Cancer
Fig.1 Prostate cancer
Prostate cancer is regarded as glandular cancer or adenocarcinoma, which starts when normal semen-secreting prostate gland cells mutation happens and changes into cancer cells. The majority of prostate cancers are slow-growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other sites of the body, particularly the lymph nodes and bones. It may initially cause no symptoms. But in later stages it can lead to difficulty urinating, blood in the urine, pain in the pelvis when urinating. The primary risk factors are age, obesity, and family history. Around 99% of cases occur in people over the age of 50 and the average age at the time of diagnosis is around 70. Mutations in BRCA1 and BRCA2 are important risk factors for ovarian cancer and breast cancer in women, have also been implicated in prostate cancer. The expression of Ki-67 by immunohistochemistry may be a significant predictor of patient outcome for men with prostate cancer.
Products List
Loading...
Compare
